Sponsor hub
Janssen Research & Development, LLC clinical trial failures
Review 93 stopped clinical trials from Janssen Research & Development, LLC, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 26 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 44
- OTHER/UNKNOWN
- 23
- EFFICACY/FUTILITY
- 19
- SAFETY
- 7
Notable sponsors
- Janssen Research & Development, LLC
- 93
Related phases
- Phase I
- 37
- Phase II
- 35
- Phase III
- 20
- Phase IV
- 1
Crawlable stopped-trial records
Open ExploreShowing up to 93 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase III Depressive Disorder, Major trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Early study termination due to insufficient efficacy.
Phase II Dermatitis, Atopic trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Terminated: futility criteria met at interim efficacy analysis.
Phase III Depressive Disorder, Major trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025)
Phase II Alzheimer Disease trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Posdinemab did not achieve statistical significance in slowing clinical decline
Phase II Lupus Nephritis trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Business Decision
Phase III Depressive Disorder, Major trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Early study termination due to insufficient efficacy.
Phase I Crohn Disease trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
The study was stopped as all post-marketing commitments had been fulfilled or released
Phase III Relapsed/ Refractory Multiple Myeloma trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Business Decision
Phase II Dengue trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
The study was stopped due to portfolio reprioritization. This decision is not based on any safety concerns.
Phase II Giant Cell Arteritis trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
The study primary endpoint was not met
Phase I Acute Leukemias trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Business Decision
Phase III Depressive Disorder, Major trial by Janssen Research & Development, LLC. Stop reason: SAFETY.
42847922MDD3002 was stopped based on the interim analysis (IA) results as recommended by the Independent Data Monitoring Committee (IDMC)
Phase III Axial Spondyloarthritis trial by Janssen Research & Development, LLC. Stop reason: SAFETY.
This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.
Phase II Alzheimer Disease trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Lupus Erythematosus, Systemic trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Study terminated early as a result of the outcome of the pre-planned Interim Analysis
Phase III Crohn's Disease trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.
Phase III Axial Spondyloarthritis trial by Janssen Research & Development, LLC. Stop reason: SAFETY.
Neither dose achieved the study's primary or major secondary endpoints. The safety profile was consistent with previous ustekinumab studies.
Phase II Depression trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Study was terminated due to sponsor portfolio decision.
Phase II Asymptomatic Amyloid-positive trial by Janssen Research & Development, LLC. Stop reason: SAFETY.
Change in benefit-risk profile for individuals with early sporadic Alzheimer Disease because of elevations in liver enzymes in subjects receiving atabecestat
Phase I Diabetes Mellitus, Type 2 trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
manufacturing-related issues
Phase I Depressive Disorder, Major trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Following discussion on pediatric strategy with HAs, it was determined that we have sufficient data to inform next steps for the seltorexant pediatric program.
Phase II Crohn Disease trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Sponsor Decision.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
business decision to end clinical development of JNJ-69095897
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
stopped because of a business decision
Phase I Depression trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
due to budget decision and wanting to pursue other research priorities
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
stopped because of a business decision
Phase II Lupus Nephritis trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Due to enrollment challenges, J\&J Innovative Medicine decided to stop screening and terminate the study early. This decision was not based on a safety concern.
Phase II Multiple Myeloma trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.
Phase I Adenocarcinoma of Lung trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical benefit observed in the Phase 1b portion of the study
Phase II Crohn Disease trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
IAC completed review of futility analysis data \& determined that futility criteria were met. As a result, Janssen made decision to stop trial immediately.
Phase III Influenza A trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Based on interim Analysis outcome being futile for FLZ3001; decision was taken to stop (early terminate) both FLZ3001/3002. There was no safety concern.
Phase II Lymphoma, Mantle-Cell trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort was terminated due to slow recruitment and aggressive disease.
Phase III Respiratory Tract Infections trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Janssen made the strategic decision to discontinue the DAISY study. This decision is not based on any safety concerns.
Phase II Respiratory Syncytial Virus Infections trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Janssen made the strategic decision to discontinue the CROCuS study. This decision is not based on any safety concerns.
Phase III Influenza A trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Study terminated early (date of study termination decision: 28 August 2020) as a result of the outcome of the pre-planned Interim Analysis.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
JNJ-54416076 program has been stopped for strategic business reasons.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Strategic business decision, not due to safety concerns
Phase I Prostatic Neoplasms trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Administrative Decision
Phase I Leukemia, Lymphocytic, Chronic, B-Cell trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Carcinoma, Non-Small-Cell Lung trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Development of JNJ-64041757 discontinued due to lack of efficacy. No further follow up data will be collected after October 22, 2018.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
The development of bermekimab in Immunology is stopped
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Sponsor Decision.
Phase I Hepatic Impairment trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Mild/moderate hepatic impairment (HI) cohorts completed with no impact to erdafitinib exposure. Severe HI cohort enrollment stopped early.
Phase III Lupus Erythematosus, Systemic trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Pre-planned IA (global study) showed lack of efficacy in this indication. No new safety signals observed, findings consistent with known profile.
Phase I Celiac Disease trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Study terminated. Sponsor decision.
Phase III Hepatitis C trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Recruitment prematurely stopped based on decision to stop HPC program (not due to safety or efficacy results) + On 31 Jan 2018 decision to stop the study
Phase II Carcinoma, Hepatocellular trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
N\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility
Phase II Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
portfolio reprioritization
Phase III Human Immunodeficiency Virus Infections trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
High SF rate (less treatment-naïve subjects \& subjects with viral load \<100000). Reevaluation in scientific position in India after internal discussion.
Phase II Respiratory Syncytial Virus trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.
Phase II Hepatitis B, Chronic trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
A strategic decision was made to not further execute the study. This decision was not based on a safety concern.
Phase II Dengue trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Feasibility of enrollment impacted by COVID
Phase II Hidradenitis Suppurativa trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Study has been prematurely terminated as the Interim Analysis 1 efficacy results met the prespecified futility criteria related to the primary endpoint.
Phase III Coronavirus Disease 2019 (COVID-19) trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
The study was terminated prematurely due to enrollment challenges.
Phase II Dermatitis, Atopic trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Premature study termination (efficacy)
Phase II Dermatitis, Atopic trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Premature Termination due to Interim Analysis (100 patients at Week 16) meeting futility.
Phase III Lymphoma, Non-Hodgkin trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).
Phase I Arthritis, Psoriatic trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
The study was stopped due to unanticipated feasibility constraints.
Phase I Hepatic Impairment trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
A strategic decision was made to discontinue the study. The decision was not based on a safety concern.
Phase II Myelodysplastic Syndromes trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
The cusatuzumab MDS strategy is under revision
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Program terminated prior to enrolling subjects
Phase IV Mycoses trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Further recruitment not possible due to COVID 19 impact. Hence a decision to close study was taken by the sponsor in Aug 2020
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Sponsor Decision.
Phase I Renal Insufficiency trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Strategic Decision
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Sponsor Decision
Phase III Metastatic Colorectal Cancer trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
The study crossed the prospective futility boundary of primary endpoint
Phase II Alopecia Areata trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Sponsor Decision.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Stopped due to a strategic decision.
Phase II Respiratory Syncytial Viruses trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
sponsor decision
Phase II Respiratory Syncytial Viruses trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Sponsor Decision
Phase I Acute Myeloid Leukemia trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
EMA/PDCO acknowledged that available results from this study do not support further clinical studies in relapsed/refractory AML paediatric patients.
Phase II Rheumatoid Arthritis trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
The decision was made to prematurely discontinue this trial due to lack of efficacy.
Phase III Nonradiographic Axial Spondylitis, Ankylosing trial by Janssen Research & Development, LLC. Stop reason: SAFETY.
This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.
Phase I Leukemia, Lymphocytic, Chronic, B-Cell trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Recent advances in the treatment of B cell malignancies resulting in new treatments being approved for marketing and many others in late stage development
Phase II Metapneumovirus trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
sponsor decision
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Trial stopped: A SAE has occured. As a measure of precaution, the trial has been stopped.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
The study has been terminated due to pending data analysis
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Terminated due to nonclinical findings
Phase I Advanced Cancer trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Janssen business decision
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Decision to discontinue development of investigational Hep C treatment regimen JNJ-4178: 3 direct acting antivirals - AL-335, ODV \& SMV.
Phase I Lupus Erythematosus, Systemic trial by Janssen Research & Development, LLC. Stop reason: SAFETY.
The decision is based on a change in the benefit risk assessment of this drug for the lupus population targeted in this study.
Phase I Hepatic Impairment trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Development program of JNJ-4178 was discontinued.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Study stopping rules were met.
Phase II Schizophrenia trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment in Cohorts 2 and 3.
Phase II Major Depressive Disorder trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Clinical Team decision to terminate the study after the results from Cohort 1 did not support conducting Cohort 2.
Phase II Active Rheumatoid Arthritis trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Study was terminated prematurely due to 2 cases of agranulocytosis in a different clinical trial with this same drug.
Phase II Prostatic Neoplasms, Castration-Resistant trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Study start delayed due to pending collection and analysis of additional phase 1 data.
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
Trial was stopped because study not required for development.
Phase III Juvenile Idiopathic Arthritis trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
Trial has failed to meet primary - and major secondary endpoints
Phase II Depression trial by Janssen Research & Development, LLC. Stop reason: SAFETY.
Evotec has indicated that this study was discontinued due to a clinical hold issued by the FDA
Phase I Healthy trial by Janssen Research & Development, LLC. Stop reason: OPERATIONAL.
Under enrollment and IP supply expiring.
Phase II Rheumatoid Arthritis trial by Janssen Research & Development, LLC. Stop reason: EFFICACY/FUTILITY.
The study was stopped due to lack of efficacy in a study conducted in a similar population,38518168ARA2002-NCT01679951.
Phase II Depressive Disorder trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.
study team decision because of IP supply issue and necessary amendment to protocol